The SWI/SNF chromatin remodeling complex, which contains more than 10 subunits with a combined molecular weight of about 2 mDa, temporarily changes the nucleosome structure using ATP hydrolysis energy so that DNA becomes less tightly bound to the histone core (Flaus and Owen-Hughes, 2001; Varga-Weisz, 2001 ; Alberts et al., 2002) . This change facilitates access to nucleosomal DNA by nuclear proteins involved in the regulation of gene transcription, DNA replication, repair, and recombination. There is accumulating evidence that this complex plays an important role in suppressing the development of cancer. Truncating mutations and homozygous deletions of hSNF5/INI1, encoding a subunit of the human SWI/SNF complex, were frequently detected in malignant rhabdoid and CNS tumors (Versteege et al., 1998; Sevenet et al., 1999) . Overexpression of hSNF5/INI1 protein in defective cells produced G1 arrest and induced apoptosis (Ae et al., 2002) , while SNF5 (À/ þ ) heterozygous mice are predisposed to tumor development (Roberts et al., 2000) . A gene encoding another subunit of the human SWI/SNF complex, BRG1, was mutated in several human cancer lines, which usually resulted in complete loss of BRG1 expression. Reintroduction of BRG1 into cells lacking its expression reversed their transformed phenotype (Wong et al., 2000) . In addition, BRG1-deficient tumor cells and cells in which a dominantnegative BRG1 was introduced were resistant to retinoblastoma tumor suppressor protein-mediated cell cycle arrest (Strobeck et al., 2000) . Furthermore, the tumor suppressor protein BRCA1 was involved in the regulation of transcription through direct interaction with BRG1 protein (Bochar et al., 2000) .
BAF180 is a recently characterized subunit of the human SWI/SNF complex Nagase et al., 2005, in preparation) . This protein with 1635 amino-acid residues and a molecular weight of 180 kDa possesses six bromodomains and two bromo-adjacent homology regions, which are conserved in chromatin remodeling factors of yeast, drosophila and Caenorhabditis elegans . BAF180 maps to the 3p21 region where allele loss is frequent and homozygous deletions have been detected in lung and breast cancer cell lines (Wistuba et al., 2000; Maitra et al., 2001; Zabarovsky et al., 2002) . Thus, genes located on this region are promising candidates for tumor suppressors (Zabarovsky et al., 2002) . Recently, we have found several BAF180 truncating mutations in breast cancer cell lines or tumors. Transfection of BAF180 into breast cancer cells lacking BAF180 resulted in growth inhibition (Nagase et al., 2005, in preparation). These findings prompted us to study the expression of BAF180 in lung cancer where 3p21 allele loss frequently occurs. Recently, a variety of studies have shown that the most common mechanism of inactivating tumor suppressor genes in lung cancer is abnormal promoter DNA methylation (Zo¨chbauer-Mu¨ller et al., 2002; Sekido et al., 2003) . Thus, we focused on mRNA and protein expression studies.
We evaluated expression of BAF180 mRNA in a total of 30 non-small-cell lung cancer (NSCLC) and 26 smallcell lung cancer (SCLC) cell lines using RT-PCR with three primer sets. A single correct sized band was detected in all samples. The intensity and size of bands (1248 bp for primer set 1, 1291 bp for primer set 2, and 1660 bp for primer set 3) were the same as that of bands from MCF-7, HeLa, and BEAS-2B (immortalized human bronchial epithelial cells) used as wild-type controls ( Figure 1) .
We also evaluated expression of BAF180 protein by Western blots with two anti-BAF180 antibodies, anti-BAF180 antibody-1 (75153) (Nagase et al., 2005, in preparation) and anti-BAF180 antibody-2 in 23 NSCLC and 23 SCLC cell lines. BAF180 expression was detected in all 46 lung cancer cell lines (Figure 2) .
Finally, we analysed BAF180 cDNA by RT-PCR and then sequenced it in five NSCLC and five SCLC cell lines, and no amino-acid sequence altering mutations were found (data not shown). Instead, we found a new isoform of BAF180 cDNA (GenBank Accession number: AY281068). This isoform is 5070 bp, longer than that previously reported by 165 bp. A BLAST search showed that this 165 bp sequence mapped between exons 27 and 28 of BAF180, suggesting that there is another exon of BAF180. The mRNA expression of this new isoform was confirmed using RT-PCR in normal bronchial epithelial cell cultures, including NHBEC (normal human bronchial epithelial cell culture) (Clonetics, San Diego, CA, USA), SAEC (small-airway epithelial cell culture) (Clonetics, San Diego, CA, USA), BEAS-2B (immortalized human bronchial epithelial cell), and HBEC1 (immortalized normal human bronchial epithelial cell line), and five NSCLC cell lines and five SCLC cell lines.
Results of SNF5/INI1 and BRG1 knockout mice are helpful to understand association between alterations in Figure 1 BAF180 mRNA expression by RT-PCR. A measure of 4 mg of total RNA were reverse transcribed with Superscript II FirstStrand Synthesis using oligodeoxythymidylic acid primer system (Invitrogen, Carlsbad, CA, USA). PCR amplification was carried out using three sets of primers previously described (Nagase et al., 2005, in preparation) in a 25 ml reaction mixture containing 1.5 mM MgCl 2 , 187.5 mM of each dNTP, 10 pmol of each primer, and 1.25 U of HotStar Taq DNA Polymerase (Qiagen, Valencia, CA, USA). Cycling conditions were one incubation of 15 min at 951C, followed by 35 cycles of a 20-s denaturation at 941C, 60-s annealing at 581C, and 90-s extension at 721C, and a final elongation at 721C for 7 min. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control as previously described (Burbee et al., 2001) . PCR products were separated by agarose gel electrophoresis and visualized after staining with ethidium bromide. MCF-7, HeLa and BEAS-2B (immortalized human bronchial epithelial cell) cells were used as positive controls. Guidi et al., 2001) . Heterozygous disruption of BRG1 also leads to tumor susceptibility in mice, and 15% of BRG1 þ /À heterozygous mice developed epithelial tumors resembling breast cancer, while no lung tumors were found (Bultman et al., 2000) . These results are consistent with the spectrum of human tumors associated with mutations in genes encoding a subunit of the human SWI/SNF complex. We examined BAF180 as a promising tumor suppressor gene candidate, because: (1) BAF180 protein is a subunit of human SWI/SNF chromatin remodeling complex; (2) BAF180 maps to the 3p21 region, where allele loss is frequent in lung and other cancers (Wistuba et al., 2000; Zabarovsky et al., 2002) ; (3) truncating BAF180 mutations leading to loss of protein expression were found in breast cancer cells; and (4) introduction of BAF180 into these breast cancer cells lead to growth inhibition (Nagase et al., 2005, in preparation) . Recently it has become clear that the most common mechanism leading to the loss of expression of genes with tumor suppressing activity in lung and other cancers is aberrant promoter methylation (Esteller and Herman, 2002; Zo¨chbauer-Mu¨ller et al., 2002; Sekido et al., 2003) . Thus, we performed detailed studies of BAF180 mRNA and protein expression. However, our results showed that both mRNA and protein expression of BAF180 appeared normal in 30 NSCLC and 26 SCLC cell lines, excluding this mechanism. In addition, if truncating mutations were present, we would have were used with dilution ratios of 1 : 1000 and 1 : 2000, respectively. Western blotting with a mouse monoclonal anti-actin antibody (Sigma, St Louis, MO, USA) at 1 : 1000 dilution was used as internal marker for loading control. Peroxidase-linked anti-rabbit IgG and anti-mouse IgG (Amersham Biosciences, Piscataway, NJ, USA) were used at 1 : 5000 dilution as a secondary antibody. The membranes were developed using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) on Hyperfilm ECL (Amersham Biosciences, Piscataway, NJ, USA). (a) Western blot analysis in NSCLC cell lines (23 tested in total with examples shown) using anti-BAF180 antibody-1. Similar results were found with anti-BAF180 antibody-2 (b) Western blot analysis in SCLC cell lines (23 tested in total with examples shown) using anti-BAF180 antibody-1 P: positive control, N: negative control. Note in (a) that breast cancer line HCC1143 with a truncating mutation of BAF180 has no detectable protein, and is used as a negative control BAF180 expression in human lung cancer I Sekine et al expected to see abnormal protein bands on Western blots, but none were found.
No insertion or deletion mutations similar to those found in breast cancers (Nagase et al., 2005, in preparation) were detected in 56 lung cancer cell line cDNAs by RT-PCR analysis using primers covering 3831 bp of BAF180 open reading cDNA sequence, and no protein truncating mutations of this gene was found by Western blot analysis. Similar to breast cancer no missense mutations may occur, no such mutations were disclosed by sequencing analysis of BAF180 cDNA. While BAF180 could exhibit haplo-insufficiency, this was not seen in the analysis of tumors developing in knockout mice for SNF5/INI1 or BRG1, or in SNF5/ INI1 in human rhabdoid tumors.
In conclusion, no abnormalities of BAF180 mRNA or protein expression were detected in a large number of NSCLC and SCLCs. We conclude that abnormalities of BAF180 are unlikely to contribute to the pathogenesis of lung cancer.
